📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Mucosis

1.1 - Company Overview

Mucosis Logo

Mucosis

Headquarter: The Netherlands
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of clinical-stage mucosal vaccines delivered needle-free via the nose or mouth, including SynGEM®, an intranasal vaccine candidate to prevent respiratory syncytial virus infection.

Products and services

🔒

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Mucosis

Romark Logo

Romark

HQ: United States Website
  • Description: Provider of small-molecule therapies for infectious diseases and cancers, offering Alinia (nitazoxanide) for diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 1+; investigational NT-300 for COVID-19 and other viral respiratory illnesses; clinical trials and R&D in viral, cancer, pain, neurodegenerative and aging-related diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Romark company profile →
ContraFect Logo

ContraFect

HQ: United States Website
  • Description: Provider of biotechnology research focused on monoclonal antibodies to treat life-threatening infectious diseases.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full ContraFect company profile →
Generate:Biomedicines Logo

Generate:Biomedicines

HQ: United States Website
  • Description: Provider of a machine learning-powered platform to create new drugs on demand across biologic modalities, accelerating therapeutic identification and validation; Chroma, an open-source AI model that programs novel proteins with targeted properties; and a clinical pipeline (GB-0895 for asthma, GB-0669 targeting SARS-CoV-2), with an expanded collaboration with Amgen to develop novel proteins.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Generate:Biomedicines company profile →
rqmicro Logo

rqmicro

HQ: Switzerland Website
  • Description: Provider of rapid pathogen separation and detection technology for microbial assessment of water and food, delivering accurate results. Offers rqmicro.COUNT, a portable single-cell counting instrument, a cloud solution to organize microbiology data, application support, and test kits for intact cell count, total cell count, and quantitative E. coli detection in water.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full rqmicro company profile →
Qpex Biopharma Logo

Qpex Biopharma

HQ: United States Website
  • Description: Provider of antibiotic agents addressing critical needs in infectious disease treatment and antimicrobial resistance for inpatient and outpatient care. Portfolio includes QPX7728, an ultra-broad-spectrum beta-lactamase inhibitor; OMNIvance (Xeruborbactam + Meropenem) for gram-negative infections; ORAvance, an oral Xeruborbactam prodrug enhancing oral beta-lactams; and QPX9003, a lipopeptide for MDR gram-negative pathogens.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Qpex Biopharma company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Mucosis

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Mucosis

2.2 - Growth funds investing in similar companies to Mucosis

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Mucosis

4.2 - Public trading comparable groups for Mucosis

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Mucosis

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Mucosis

What does Mucosis do?

Mucosis is a provider of clinical-stage mucosal vaccines delivered needle-free via the nose or mouth, including SynGEM®, an intranasal vaccine candidate to prevent respiratory syncytial virus infection.

Who are Mucosis's competitors?

Mucosis's competitors and similar companies include Romark, ContraFect, Generate:Biomedicines, rqmicro, and Qpex Biopharma.

Where is Mucosis headquartered?

Mucosis is headquartered in The Netherlands.

How many employees does Mucosis have?

Mucosis has 1,000 employees 🔒.

When was Mucosis founded?

Mucosis was founded in 2010 🔒.

What sector and industry vertical is Mucosis in?

Mucosis is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Mucosis

Who are the top strategic acquirers in Mucosis's sector and industry

Top strategic M&A buyers and acquirers in Mucosis's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Mucosis?

Top strategic M&A buyers groups and sectors for Mucosis include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Mucosis's sector and industry vertical

Which are the top PE firms investing in Mucosis's sector and industry vertical?

Top PE firms investing in Mucosis's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Mucosis's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Mucosis's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Mucosis's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Mucosis include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Mucosis's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Mucosis?

The key public trading comparables and valuation benchmarks for Mucosis include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Mucosis for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Mucosis with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Mucosis's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Mucosis with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Mucosis's' sector and industry vertical?

Access recent funding rounds and capital raises in Mucosis's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Mucosis